Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular.  Therefore, they are associated with thromboembolic and bleeding risk. This study looked mortality predictors after successful TAVR in the Galileo trial.  Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular.  Mortality predictors were age >85,…